Epsilogen has also announced that it has in-licenced exclusive global rights to MOv18 IgE, an anti-folate receptor alpha IgE antibody from King’s College London that is the first therapeutic IgE antibody to enter clinical trials. Cancer Research UK is sponsoring and conducting the on-going phase I clinical trial in ovarian cancer patients resistant to chemotherapy. Interim data from this clinical trial will be presented at the forthcoming virtual meeting of the American Association of Cancer Research (AACR) which begins on April 27th.
The £3m investment from existing investors will allow Epsilogen to continue with the clinical development of MOv18 IgE and initiate a comprehensive manufacturing programme with a leading contract development and manufacturing organisation. Funds will also be used to progress a portfolio of IgE antibody candidates against a variety of cancers.
Dr Tanel Ozdemir, Investment Analyst at UCL Technology Fund commented: “UCLTF is excited by Epsilogen’s world-leading IgE antibody technology and what it could mean for cancer therapeutics. The team has made great progress since our last investment in November 2018 and we are delighted to continue supporting them as they strive to bring what could be a clinically transformative technology closer to patients. Alongside our coinvestors Epidarex Capital and Alsa Holdings, we truly believe this is an exicting juncture for the Company.”
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half life. The company has raised Series A finance from Epidarex Capital, ALSA Holdings and UCL Technology Fund.